These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23969422)

  • 1. Comparing predictors of conversion to Alzheimer's disease using the disease state index.
    Muñoz-Ruiz MÁ; Hall A; Mattila J; Koikkalainen J; Herukka SK; Vanninen R; Liu Y; Lötjönen J; Soininen H;
    Neurodegener Dis; 2014; 13(2-3):200-2. PubMed ID: 23969422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease.
    Hall A; Muñoz-Ruiz M; Mattila J; Koikkalainen J; Tsolaki M; Mecocci P; Kloszewska I; Vellas B; Lovestone S; Visser PJ; Lötjonen J; Soininen H; ; ;
    J Alzheimers Dis; 2015; 44(1):79-92. PubMed ID: 25201784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort.
    Runtti H; Mattila J; van Gils M; Koikkalainen J; Soininen H; Lötjönen J;
    J Alzheimers Dis; 2014; 39(1):49-61. PubMed ID: 24121959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease state fingerprint in frontotemporal degeneration with reference to Alzheimer's disease and mild cognitive impairment.
    Muñoz-Ruiz MÁ; Hartikainen P; Hall A; Mattila J; Koikkalainen J; Herukka SK; Julkunen V; Vanninen R; Liu Y; Lötjönen J; Soininen H
    J Alzheimers Dis; 2013; 35(4):727-39. PubMed ID: 23455991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia.
    Eckerström C; Olsson E; Bjerke M; Malmgren H; Edman A; Wallin A; Nordlund A
    J Alzheimers Dis; 2013; 36(3):421-31. PubMed ID: 23635408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
    Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
    J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
    Schmand B; Eikelenboom P; van Gool WA;
    J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
    Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
    Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study.
    Damian M; Hausner L; Jekel K; Richter M; Froelich L; Almkvist O; Boada M; Bullock R; De Deyn PP; Frisoni GB; Hampel H; Jones RW; Kehoe P; Lenoir H; Minthon L; Olde Rikkert MG; Rodriguez G; Scheltens P; Soininen H; Spiru L; Touchon J; Tsolaki M; Vellas B; Verhey FR; Winblad B; Wahlund LO; Wilcock G; Visser PJ
    Dement Geriatr Cogn Disord; 2013; 36(1-2):1-19. PubMed ID: 23651945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study.
    Tondelli M; Bedin R; Chiari A; Molinari MA; Bonifacio G; Lelli N; Trenti T; Nichelli P
    Clin Chem Lab Med; 2015 Feb; 53(3):453-60. PubMed ID: 25274948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles.
    Park MH; Han C
    Int Psychogeriatr; 2015 Mar; 27(3):429-37. PubMed ID: 25255915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression.
    Furney SJ; Kronenberg D; Simmons A; Güntert A; Dobson RJ; Proitsi P; Wahlund LO; Kloszewska I; Mecocci P; Soininen H; Tsolaki M; Vellas B; Spenger C; Lovestone S
    J Alzheimers Dis; 2011; 26 Suppl 3():395-405. PubMed ID: 21971479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study.
    Eckerström C; Olsson E; Klasson N; Berge J; Nordlund A; Bjerke M; Wallin A
    J Alzheimers Dis; 2015; 44(1):205-14. PubMed ID: 25201779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease.
    Gainotti G; Quaranta D; Vita MG; Marra C
    J Alzheimers Dis; 2014; 38(3):481-95. PubMed ID: 24002185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk classification in mild cognitive impairment patients for developing Alzheimer's disease.
    Zhou B; Nakatani E; Teramukai S; Nagai Y; Fukushima M;
    J Alzheimers Dis; 2012; 30(2):367-75. PubMed ID: 22426014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.